Verburg FA - Search Results

1

2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma.

Lebbink CA, Links TP, Czarniecka A, Dias RP, Elisei R, Izatt L, Krude H, Lorenz K, Luster M, Newbold K, Piccardo A, Sobrinho-Simões M, Takano T, Paul van Trotsenburg AS, Verburg FA, van Santen HM. Lebbink CA, et al. Among authors: verburg fa. Eur Thyroid J. 2022 Nov 29;11(6):e220146. doi: 10.1530/ETJ-22-0146. Print 2022 Dec 1. Eur Thyroid J. 2022. PMID: 36228315 Free PMC article.

2

Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Verburg FA, Dietlein M, Lassmann M, Luster M, Reiners C. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2009 Mar;36(3):343-6. doi: 10.1007/s00259-008-0997-5. Eur J Nucl Med Mol Imaging. 2009. PMID: 19050874 Review. No abstract available.

3

Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma.

Verburg FA, Mäder U, Luster M, Reiners C. Verburg FA, et al. Clin Endocrinol (Oxf). 2009 Aug;71(2):291-7. doi: 10.1111/j.1365-2265.2008.03482.x. Epub 2008 Dec 3. Clin Endocrinol (Oxf). 2009. PMID: 19067727

4

Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.

Verburg FA, Mäder U, Luster M, Reiners C. Verburg FA, et al. Eur J Endocrinol. 2009 Apr;160(4):619-24. doi: 10.1530/EJE-08-0805. Epub 2009 Jan 21. Eur J Endocrinol. 2009. PMID: 19158232

5

Intratracheal growth of recurrent benign goiter.

Verburg FA, Gasser M, Beissert M, Geissinger E, Luster M, Reiners C. Verburg FA, et al. Thyroid. 2009 Sep;19(9):1009-11. doi: 10.1089/thy.2009.0067. Thyroid. 2009. PMID: 19731981

6

A comparison of prognostic classification systems for differentiated thyroid carcinoma.

Verburg FA, Mäder U, Kruitwagen CL, Luster M, Reiners C. Verburg FA, et al. Clin Endocrinol (Oxf). 2010 Jun;72(6):830-8. doi: 10.1111/j.1365-2265.2009.03734.x. Epub 2009 Oct 31. Clin Endocrinol (Oxf). 2010. PMID: 19863574

7

Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.

Verburg FA, Hänscheid H, Biko J, Hategan MC, Lassmann M, Kreissl MC, Reiners C, Luster M. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2010 May;37(5):896-903. doi: 10.1007/s00259-009-1303-x. Epub 2009 Dec 24. Eur J Nucl Med Mol Imaging. 2010. PMID: 20033685

8

No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Verburg FA, Stokkel MP, Düren C, Verkooijen RB, Mäder U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):276-83. doi: 10.1007/s00259-009-1315-6. Epub 2009 Nov 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20091165

9

Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Luster M, Karges W, Zeich K, Pauls S, Verburg FA, Dralle H, Glatting G, Buck AK, Solbach C, Neumaier B, Reske SN, Mottaghy FM. Luster M, et al. Among authors: verburg fa. Thyroid. 2010 May;20(5):527-33. doi: 10.1089/thy.2009.0342. Thyroid. 2010. PMID: 20450432

10

The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients.

Verburg FA, Lassmann M, Mäder U, Luster M, Reiners C, Hänscheid H. Verburg FA, et al. Eur J Nucl Med Mol Imaging. 2011 Apr;38(4):673-80. doi: 10.1007/s00259-010-1689-5. Epub 2011 Jan 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21210115

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

254 results

Search Page